Contributions
Abstract: P1231
Type: Poster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Background: MS patients can be offered a wide range of immunomodulating treatments (DMT) nowadays. Many new potential treatments for MS are in phase 2 or 3 clinical trials and will soon contribute to the broad choice of possible therapies. Disease modifying drugs (DMD) can be prescribed according to the individual neurologists" preferences with local limitations, traditional strategy of 1st or 2nd line treatments, tailored to an individual patient"s medical status and predicted response, or be in line with MS guidelines. In such a situation, the space and time patterns of MS treatment are difficult to acquire.
Objectives: In the advances of treatment options, development of a real-time, easy and flexible monitoring system of DMD use, has been highly requested. Flexibility meant a possibility to select single or any group of DMDs with other parameters defining a particular subgroup. The intention was to implement both cross sectional comparisons and longitudinal follow-ups of treatment strategies. The aim of the project was to design a system, with an intuitive user interface, on-the-fly calculations and easy access.
Methods: All the neurological clinics in Sweden are involved in gathering DMT data on MS patients in Swedish MS Registry (SMSreg) on a regular, however not mandatory basis. SMSreg has over 82% coverage of prevalent MS patients i.e. 15.7 of 19.5 thousand estimated patients. Total number of registered DMDs is 28.7 thousand on 12.7 thousand unique MS patients with treatment data.
Results: Real-time monitoring of DMDs in VAP is divided into two groups of customizable diagrams for cross sectional comparisons (daily status) and longitudinal ones. The user can compare the drugs use in many ways. Started, discontinued and ongoing treatments can be selected. All, treatment-naïve or further treatment patients can be chosen. Divisions by gender, clinical course, disease duration and age groups are implemented. Monitoring can be done on five administrative levels from own neurologist"s patients up to the country level. The system is available through an intuitive user interface supported with simple graphical selection tools.
Conclusions: Monitoring of DMT with the help of real-time VAP reports offers a wide range of flexible, real-time visualization and statistics on a national level. It satisfies the needs of providing detailed information on treatment patterns back to decision makers, clinicians and researchers, which are otherwise challenging to gather.
Disclosure: Leszek Stawiarz declares no conflict of interests.
Eva Hagel declares no conflict of interests.
Hakan Eriksson declares no conflict of interests.
Jan Hillert received honoraria for serving on advisory boards for Biogen and Novartis and speaker´s fees from Biogen, MerckSerono, BayerSchering, Teva and SanofiGenzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, SanofiGenzyme, MerckSerono, TEVA, Novartis and BayerSchering. His MS research is funded by the Swedish Research Council and the Swedish Brain Foundation.
Abstract: P1231
Type: Poster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Background: MS patients can be offered a wide range of immunomodulating treatments (DMT) nowadays. Many new potential treatments for MS are in phase 2 or 3 clinical trials and will soon contribute to the broad choice of possible therapies. Disease modifying drugs (DMD) can be prescribed according to the individual neurologists" preferences with local limitations, traditional strategy of 1st or 2nd line treatments, tailored to an individual patient"s medical status and predicted response, or be in line with MS guidelines. In such a situation, the space and time patterns of MS treatment are difficult to acquire.
Objectives: In the advances of treatment options, development of a real-time, easy and flexible monitoring system of DMD use, has been highly requested. Flexibility meant a possibility to select single or any group of DMDs with other parameters defining a particular subgroup. The intention was to implement both cross sectional comparisons and longitudinal follow-ups of treatment strategies. The aim of the project was to design a system, with an intuitive user interface, on-the-fly calculations and easy access.
Methods: All the neurological clinics in Sweden are involved in gathering DMT data on MS patients in Swedish MS Registry (SMSreg) on a regular, however not mandatory basis. SMSreg has over 82% coverage of prevalent MS patients i.e. 15.7 of 19.5 thousand estimated patients. Total number of registered DMDs is 28.7 thousand on 12.7 thousand unique MS patients with treatment data.
Results: Real-time monitoring of DMDs in VAP is divided into two groups of customizable diagrams for cross sectional comparisons (daily status) and longitudinal ones. The user can compare the drugs use in many ways. Started, discontinued and ongoing treatments can be selected. All, treatment-naïve or further treatment patients can be chosen. Divisions by gender, clinical course, disease duration and age groups are implemented. Monitoring can be done on five administrative levels from own neurologist"s patients up to the country level. The system is available through an intuitive user interface supported with simple graphical selection tools.
Conclusions: Monitoring of DMT with the help of real-time VAP reports offers a wide range of flexible, real-time visualization and statistics on a national level. It satisfies the needs of providing detailed information on treatment patterns back to decision makers, clinicians and researchers, which are otherwise challenging to gather.
Disclosure: Leszek Stawiarz declares no conflict of interests.
Eva Hagel declares no conflict of interests.
Hakan Eriksson declares no conflict of interests.
Jan Hillert received honoraria for serving on advisory boards for Biogen and Novartis and speaker´s fees from Biogen, MerckSerono, BayerSchering, Teva and SanofiGenzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, SanofiGenzyme, MerckSerono, TEVA, Novartis and BayerSchering. His MS research is funded by the Swedish Research Council and the Swedish Brain Foundation.